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Abstract
Background: Senna alata (S. alata) has numerous pharmacological activities including anti-lipogenic effect in high-
fat diet (HFD)-induced obese mice. The present study investigated the effect of Senna alata (S. alata) leaf extracts
on the regulation of abnormal glucose metabolism in HFD-induced obese mice.
Methods: Male ICR mice were induced to become obese by being fed a HFD (45 kcal% lard fat) for 12 weeks.
During the last 6 weeks of diet feeding, the obese mice were treated with the water extract of S. alata leaf at 250
and 500 mg/kg/day. After 6 weeks of treatment, blood was collected for measuring biochemical parameters. The
liver, epididymal fat and skeletal muscle tissues were excised and kept for determining histology and western blot
analysis.
Results: Treatment with S. alata (250 and 500 mg/kg) significantly reduced hyperglycemia, hyperinsulinemia, and
hyperleptinemia. The glucose intolerance was improved by S. alata. The elevated monocyte chemoattractant
protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) levels in obese mice were reduced in S. alata treatment. The
level of serum adiponectin was increased in obese mice treated with S. alata (250 and 500 mg/kg). The epididymal
fat weight was reduced in S. alata treatment. The enlarged adipocyte size was smaller in obese mice treated
with S. alata. In comparison with the obese control mice, the mice treated with S. alata showed a significant
reduction of liver glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) proteins.
Moreover, S. alata up-regulated the liver and muscle adenosine monophosphate-activated protein kinase
phosphorylation (pAMPK) and muscle glucose transporter 4 (GLUT4).
Conclusions: The results indicate that the restoration of impaired glucose metabolism of S. alata may be
associated with reduced hepatic gluconeogenesis and increased glucose uptake via AMPK activation.
Keywords: Senna alata, Obesity, Insulin resistance
Abbreviations: AMPK, Adenosine monophosphate-activated protein kinase; G6Pase, Glucose-6-phosphatase;
GLUT4, Glucose transporter 4; HFD, High-fat diet; LFD, Low-fat diet; PEPCK, Phosphoenolpyruvate carboxykinase
Background
Obesity is a condition that is strongly associated with
insulin resistance and diabetes. There are several
underlying mechanisms which explain the association.
For example, in studies using obesity-related insulin
resistance models, the up-regulation of hepatic
phosphoenolpyruvate carboxykinase (PEPCK) and
glucose-6-phosphatase (G6Pase) enzymes was found
to induce an increase in glucose production [1, 2].
Furthermore, impairment of glucose transporter 4
(GLUT4) expression and GLUT4 translocation and/or in-
sulin signaling may affect insulin-stimulated glucose up-
take, also resulting in insulin resistance and type 2
diabetes mellitus (T2DM) [3]. Increased GLUT4 expres-
sion or translocation to the plasma membrane can be
regulated by activation of adenosine monophosphate-
activated protein kinase (AMPK) via insulin-independent
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mechanism [4]. In liver, AMPK controls glucose homeo-
stasis mainly through the inhibition of gluconeogenic gene
expression and hepatic glucose production [5]. AMPKα2,
a major subunit of AMPK, has been found to play an im-
portant role in glucose homeostasis [6]. In mice fed with
high-fat diet (HFD), absence of AMPKα2 in skeletal
muscle subunit led to a development of glucose intoler-
ance and insulin resistance [6]. AMPK is thus considered
a therapeutic target in the prevention and treatment of
T2DM [7–9]. Activation of AMPK in the liver and muscle
is expected to elicit beneficial metabolic effects with the
potential to improve the defects associated with T2DM
and the metabolic syndrome [8].
Senna alata (S. alata) is a tropical plant found in
many countries, including Thailand. It has numerous
pharmacological activities such as antitumor [10], an-
thelmintic [11], anti-bacterial [12], anti-oxidant and anti-
inflammatory [13], and anti-diabetic activities [14]. A re-
cent study found that S. alata (250 and 500 mg/kg)
improved abnormal lipid metabolism by suppressing
hepatic lipogenic genes, sterol regulatory element bind-
ing protein 1c (SREBP1c), fatty acid synthase (FAS) and
acetyl-CoA carboxylase (ACC) [15]. However, the effect
of S. alata in regulating glucose metabolism in obesity-
related insulin resistance is little known. The present
study investigated the effect of S. alata on impaired glu-
cose metabolism using HFD-induced obese mice and
measuring the parameters associated with hepatic




All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO, USA). The low-fat diet (LFD) and high-fat
diet (HFD) were purchased from Research Diets (New
Brunswick, NJ, USA). Anti-G6Pase, anti-GLUT4, and
anti-β actin were purchased from Santa Cruz Biotech-
nology, Inc. (Dallas, TX, USA). Anti-phospho-AMPKα
Thr172 (pAMPK), anti-AMPKα, and polyvinylidene
difluoride (PVDF) membranes were purchased from
EMD Millipore (Billerica, MA, USA).
Plant preparation and extraction
The S. alata leaves were collected between July and
September 2013 in Buriram, Thailand. A voucher speci-
men (SKP 034 19 01 01) was given by the Faculty of
Pharmaceutical Sciences, Prince of Songkla University,
Thailand. The dried leaves were extracted three times
with water at 100 °C for 30 min. The extract was filtered
and lyophilized. The yield of dried extract was 15.58 %
of the starting dry weight of the leaves. Distilled water
was used for dissolving S. alata extracts prior to feeding
to mice.
Animals, diets, and experimental design
The animal experimental protocol was reviewed by the
Animal Ethics Committee of Thammasat University,
Pathum Thani, Thailand (Rec. No. AE 009/2014). ICR
male mice weighing 20–25 g (National Laboratory Animal
Center, Mahidol University, Nakhon Pathom, Thailand)
were housed under standard conditions with free access
to water and fed with LFD for a week (3.85 kcal/g total
energy, 10 % lard fat, 20 % protein, and 70 % carbohy-
drate). Then they were fed with LFD (normal control
mice) or HFD (obese mice) containing 4.73 kcal/g total
energy, 45 % lard fat, 20 % protein, and 35 % carbohydrate
for 12 weeks. During the last 6 weeks period of diet, nor-
mal control mice (NC, n = 8) were daily given distilled
water (2 mL/kg) via oral gavage, and 24 obese mice, di-
vided into three groups (n = 8 per group) were orally ad-
ministered with 2 mL/kg of distilled water (obese control
mice: OB), or 250 mg/kg, or 500 mg/kg of S. alata ex-
tracts. At the 5th week of treatment period, all mice were
subjected to given oral glucose tolerance test as detailed
below. After the 6-weeks treatment period, all mice were
sacrificed using isoflurane anesthesia. Whole blood sam-
ples were collected by cardiac puncture, and blood glucose
level was measured. The serum samples were further ana-
lyzed for insulin, leptin, adiponectin, monocyte chemo-
attractant protein-1 (MCP-1), and tumor necrosis factor-α
(TNF-α) levels. Liver, epididymal fat, and skeletal muscle
tissues were taken for histology and western blot analysis.
Oral glucose tolerance test (OGTT)
An OGTT was performed on the mice after 6 h of
fasting. Mice were orally loaded with 50 % glucose
(2.0 g/kg). Tail vein blood samples were collected be-
fore, and after glucose loading at 20, 60 and 120 min
to determine glucose concentrations using an Accu-
Check glucometer (Roche Diagnostics, Manheim,
Germany). Area under the curve (AUC) for glucose
over time was calculated using a trapezoidal method.
Serum insulin, leptin, adiponectin, and MCP-1 levels
Serum insulin, leptin, and adiponectin concentrations
were measured using ELISA kit assay (EMD Millipore,
Billerica, MA, USA). Serum MCP-1 was measured using
ELISA kit assay (Thermo Scientific, Rockford, IL, USA).
The index of the homeostasis model assessment of insu-
lin resistance (HOMA-IR) was calculated as an indicator
of insulin sensitivity according to the following formula:
[insulin (μIU) × glucose (mM)]/22.5 [16].
Western blot analysis
Liver and skeletal muscle tissues were homogenized and
extracted with TPER® mixed with Halt® protease inhibi-
tor (Thermo Scientific, Rockford, IL, USA). Protein sam-
ples (40 μg) were subjected to 12 % SDS-polyacrylamide
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gel electrophoresis and transferred to PVDF membranes,
which were then probed with anti-PEPCK, anti-G6Pase,
anti-pAMPK, anti-AMPK, anti-GLUT4, and anti-actin
primary antibodies (diluted 1:500) overnight at 4 °C. Fol-
lowing the incubation with horseradish peroxidase-
conjugated secondary antibody (diluted 1:5000) for 2 h
at room temperature, and the blots were developed in
Clarity™ Western ECL substrate (Bio-rad, Brea, CA,
USA). Images were obtained with an Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE,
USA), and band intensities were quantified by densitom-
etry using a Gel-Pro™ Analyzer version 3.1 software
(MediaCybernetics, Rockville, MD, USA). All relative
target proteins were normalized to actin.
Epididymal fat histology
The epididymal fat tissues were fixed with 10 % for-
malin, embedded in paraffin, and sectioned and
stained with hematoxylin and eosin (H&E). The histo-
logical changes were explored using a light micro-
scope (Olympus, Tokyo, Japan). The adipocyte size
was determined using an ImageJ software program
(National Institute of Health, Bethesda, MD, USA).
Statistical analysis
All values were expressed as mean ± standard error of
the mean (SEM). Following the performance by one-way
analysis of variance (ANOVA) followed by a Tukey’s
post-hoc test for multiple comparisons using SigmaStat
(Systat Software, San Jose, CA, USA). P < 0.05 was
considered to be significant.
Results
Effect of S. alata extracts on metabolic parameters
As shown in Table 1, after 12 weeks of HFD feeding, the
body weight of obese control mice was significantly in-
creased as compared to normal control mice. There was a
slight decrease in body weight between the obese control
group and S. alata-treated groups, but this data is not sta-
tistically significant. Obese mice treated with S. alata (250
and 500 mg/kg) significantly decreased FBG and serum
insulin, with improved HOMA-IR. S. alata (250 and
500 mg/kg) significantly reduced the serum leptin whereas
the serum adiponectin was significantly increased com-
pared with obese control mice (Table 1). Moreover, the el-
evated serum MCP-1 and TNF-α were significantly
reduced by S. alata treatment (Table 1). In OGTT, obese
control mice had high blood glucose level at 20, 60, and
120 min after glucose loading compared with normal con-
trol mice (Fig. 1a), but obese-treated S. alata groups (250
and 500 mg/kg) significantly suppressed the elevated
blood glucose at 120 min. The average AUC of OGTT of
S. alata groups was less than that of obese control mice
(Fig. 1b), suggesting that S. alata improved glucose toler-
ance ability. However, these parameters were not signifi-
cantly different between two S. alata doses.
Effect of S. alata extracts on hepatic PEPCK, G6Pase and
pAMPK protein expressions
Hepatic gluconeogenic enzymes, PEPCK and G6Pase were
elevated in OB mice relative to NC mice (Fig. 2a and b). S.
alata (250 and 500 mg/kg) significantly reduced PEPCK
and G6Pase protein expression compared to the OB mice.
Furthermore, the AMPK phosphorylation was increased
in obese mice treated with S. alata compared with obese
control mice (Fig. 2c). While S. alata at both doses had a
significant effect on these parameters, S. alata at 500 mg/
kg especially reduced gluconeogenic enzymes and in-
creased AMPK phosphorylation protein expression to a
level near the control.
Effect of S. alata extracts on muscle pAMPK and plasma
membrane GLUT4 protein expressions
Expression of pAMPK and GLUT4 proteins were signifi-
cantly decreased in the OB group compared with NC
group (Fig. 3a and b). The expressions of these two
Table 1 Effect of S. alata leaf extract on metabolic parameters in HFD-induced obese mice
Groups NC OB OB + S. alata (mg/kg)
250 500
Body weight (g) 44.0 ± 0.70 50.0 ± 1.68 * 48.6 ± 1.20 * 48.7 ± 1.13 *
FBG (mM) 5.5 ± 0.14 9.9 ± 0.61* 7.5 ± 0.28 *, ** 7.4 ± 0.16 *, **
Insulin (ng/mL) 0.6 ± 0.06 3.6 ± 0.23 * 2.4 ± 0.26 *, ** 2.3 ± 0.25 *, **
HOMA-IR 3.8 ± 0.41 37.7 ± 3.08 * 19.2 ± 1.84 *, ** 18.7 ± 2.96 *, **
Leptin (ng/mL) 1.3 ± 0.28 15.0 ± 1.15 * 10.3 ± 0.72 *, ** 10.0 ± 0.72 *, **
Adiponectin (pg/mL) 7.6 ± 0.25 5.9 ± 0.44 * 9.1 ± 0.31 *, ** 9.6 ± 0.26 *, **
MCP-1 (pg/mL) 3.9 ± 0.46 16.2 ± 1.10 * 5.0 ± 0.67 * 3.9 ± 0.50 *
TNF-α (pg/mL) 5.1 ± 0.70 18.5 ± 1.52 * 10.6 ± 0.72 *, ** 8.7 ± 0.61 *, **
Values are represented as mean ± SEM (n = 8). * P < 0.05 compared to normal control group
** P < 0.05 compared to obese control group. NC normal control mice fed with LFD, OB obese mice fed with HFD, FBG fasting blood glucose, MCP-1 monocyte
chemoattractant protein-1, TNF-α tumor necrosis factor-α
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proteins were up-regulated in the OB mice treated with
S. alata (250 and 500 mg/kg) compared to the OB
control group.
Effect of S. alata extracts on epididymal fat histology
The epididymal fat weight of OB group was significantly
increased compared with NC group (Fig. 4a). However,
treatment of S. alata (250 and 500 mg/kg) significantly
decreased the fat weight as compared with OB group.
The average size of fat cells of OB group was also larger
than NC group (Fig. 4b–f ), but treatment with S. alata
significantly decreased the enlarged size of adipocytes
compared with the OB group.
Discussion
A previous study showed that treatment with S. alata leaf
extract has potent anti-lipogenic activity in mice fed with
HFD [15]. However, its activity in improving impaired glu-
cose metabolism in obesity-related insulin resistance is
unclear. In the present study, we demonstrated that treat-
ment with S. alata leaf extract also improved glucose
metabolism in HFD-induced obese mice and led to reduc-
tion in the hypertrophic adipocyte size.
In this study, we found that administration of S. alata
extract can decrease FBG, insulin, leptin, and MCP-1
levels, indicating that S. alata extract may lead to an im-
provement of insulin resistant condition. When further
examining the effect of S. alata extract on the glucose
tolerance test, it was found that treated obese mice re-
lieved glucose intolerance and insulin sensitivity as
shown by decreasing HOMA-IR index. These findings
support the effects of S. alata in regulating glucose
metabolism in obese-related insulin resistant mice.
To better understand the underlying mechanism by
which S. alata mediates the beneficial effects on obese
animals, the expressions of proteins involving in energy
metabolism were investigated. There have been several
studies indicating that insulin resistance and T2DM are
associated with the increase of two key enzymes involved
in the hepatic glucose production, PEPCK and G6Pase
[17, 18]. In accordance with the other studies, we found
the correlation of PEPCK and G6Pase expression in obese
Fig. 1 Effect of S. alata leaf extract on OGTT (a), and mean of AUC in OGTT (b) in HFD-induced obese mice. Values are represented as mean ±
SEM (n = 8). # P < 0.05 compared to normal control group. * P < 0.05 compared to obese control group. NC: normal control mice fed with LFD,
OB: obese control mice fed with HFD, SA: S. alata extract
Fig. 2 Effect of S. alata leaf extract on hepatic protein expression of PEPCK (a), G6Pase (b), and pAMPK (c) in HFD-induced obese mice. Values are
represented as mean ± SEM (n = 8). # P < 0.05 compared to normal control group. * P < 0.05 compared to obese control group. NC: normal control
mice fed with LFD, OB: obese control mice fed with HFD, SA: S. alata extract
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mice; however, our results showed that obese mice receiv-
ing the S. alata extracts had decreasing expressions of
PEPCK and G6Pase in liver tissue. These results indicate
the possible mechanism of S. alata in improving glucose
metabolism via suppressing hepatic glucose production.
AMPK is a major enzyme that regulates glucose and
lipid metabolism in tissues including liver, adipose, and
muscle. Activation of AMPK can inhibit lipid synthesis
and improve insulin action [19, 20]. Important mecha-
nisms of AMPK involved in the control of diabetes and
obesity include prevention of (glucose or lipid) overpro-
duction through down-regulation of SREBP1 gene, and
inhibition of lipogenic and gluconeogenic enzymes as ev-
idenced by the liver-specific AMPKα2 knockout mice
developed hyperglycemia and glucose intolerance as a
result of increased hepatic glucose production [21]. A
Fig. 3 Effect of S. alata leaf extract on muscle protein expression of pAMPK (a) and plasma membrane GLUT4 (b) in HFD-induced obese mice.
Values are represented as mean ± SEM (n = 8). # P < 0.05 compared to normal control group. * P < 0.05 compared to obese control group.
NC: normal control mice fed with LFD, OB: obese control mice fed with HFD, SA: S. alata extract
Fig. 4 Effect of S. alata on epididymal fat weight (a), adipocyte size (b), and histological examination of epididymal fat (c–f) (H&E staining, 40×) in
HFD-induced obese mice. The histological examination of fat tissue exhibited the reduction in fat cell size after 6 weeks of S. alata administration.
Values are represented as mean ± SEM (n = 8). # P < 0.05 compared to normal control group. * P < 0.05 compared to obese control group.
NC: normal control mice fed with LFD, OB: obese control mice fed with HFD, SA: S. alata extract
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study showed that the stimulation of AMPK in wild-type
mice dramatically reduced hepatic glucose output [5].
Our study found that S. alata treatment reduced the
protein expressions of hepatic gluconeogenic enzymes,
PEPCK and G6Pase. S. alata treatment was also found
to significantly decrease hepatic and serum lipid content
via down-regulating expressions of SREBP1c and lipo-
genic enzyme (FAS and ACC) [15]. The present study
showed that S. alata extract significantly up-regulated
protein expression of AMPK phosphorylation in liver
and skeletal muscle tissues. This finding indicates that
S. alata has the ability to reduce hyperglycemia
through AMPK activities – a similar mechanism to
AMPK activators such as metformin, which decreases
blood glucose level by inhibiting hepatic glucose pro-
duction and stimulating glucose disposal in skeletal
muscle [22].
Phosphorylation of AMPK is also a major regulator of
GLUT4 translocation during exercise or in response to
some anti-diabetic agents such as AICAR or metformin.
It results in the stimulation of GLUT4 translocation to
plasma membrane and elevation of glucose uptake in
skeletal muscles [23]. In the present study, we observed
that S. alata was able to stimulate GLUT4 translocation
in muscle cells. It is possible that the enhanced GLUT4
translocation by S. alata extract is controlled by AMPK
phosphorylation.
Secretion of adiponectin has also been reported to in-
duce glucose uptake and GLUT4 translocation in rat
skeletal muscle cells [24], and AMPK is activated by adi-
ponectin in skeletal muscle [25]. Increased adiponectin
level, which stimulates glucose uptake and fatty oxida-
tion and inhibits the expression of gluconeogenic genes,
is thus beneficial for insulin resistance [26]. In this study,
it was found that serum adiponectin levels were signifi-
cantly reduced in HFD-induced obese mice but were re-
versed significantly to the level higher than the control
after the obese mice receiving S. alata. Thus, it is pos-
sible that S. alata has a beneficial effect on glucose and
lipid metabolism by AMPK activation which may be me-
diated via increasing adiponectin secretion and/or via
direct activation of AMPK.
The epididymal fat histologic results in this study also
revealed that the number of large adipocytes was de-
creased while the number of small adipocytes was in-
creased among mice receiving S. alata. The adipose
tissue mass in obese mice treated with S. alata is lower
than in obese control mice. It is of interest to note that
S. alata efficiently reduces adipose mass and adipocyte
hypertrophy in obese mice. A study showed that AMPK-
knockout mice had higher body weight than wild-type
mice, with a specific increase in adipose tissue mass
[27]. This indicates that AMPK activation exerts an anti-
lipogenic effect and AMPK might be a potential target
for the treatment of obesity. It is thus likely that the de-
creases in size and mass of adipose tissue of obese mice
receiving S. alata, as found in this study, are associated
with the AMPK activation. The hypertrophy of fat cell is
known to be closely related to metabolic diseases [28].
Insulin resistance in adipose tissue causes the increased
release of free fatty acid, which in turn, increased hepatic
generation of triglyceride (TG). Moreover, the accumula-
tion of fat and cell size in adipose tissue are mainly from
the circulating TG [29]. There was a report that S. alata
can decrease hepatic TG accumulation [15]. It is possible
that decreasing mass and size of fat cells, an effect of S.
alata, results from decreasing TG accumulation or in-
creasing hepatic lipid metabolism.
Furthermore, AMPK activation was shown to relieve
lipopolysaccharide (LPS)-induced inflammation in mac-
rophages [30]. TNF-α is the proinflammatory cytokine
that defects insulin function in the peripheral tissue and
has a direct impact in obesity-related insulin resistance
[31]. Our study showed that S. alata decreased proin-
flammatory cytokine, MCP-1 and TNF-α. Therefore, it
appears that S. alata-induced AMPK might also contrib-
ute to the suppression of inflammatory responses, which
would lead to improvement in metabolic disorders such
as insulin resistance in obesity.
Several phytochemicals such as berberine, quercetin,
and resveratrol act as AMPK activators and have effects
on metabolic disorders including hyperlipidemia, insulin
resistance, and obesity [32–35]. Our previous study dem-
onstrated that S. alata leaf extract contained flavonoid
and polyphenol [15]. Although we did not identify the
specific active ingredients, we think that these contents
may be associated with improvement of impaired glucose
metabolism in HFD-fed mice. In addition, our previous
study showed the administration of S.alata at 2000 mg/kg
for 7 days had no toxicity in mice [15]. In the present
study, mice treated with of S. alata did not show any side
effects such as diarrhea during the 6-week study period.
Conclusions
In conclusion, this study demonstrated that S. alata had
effects on regulation of abnormal glucose metabolism in
HFD-fed mice, and such effect might be associated with
increased phosphorylation of AMPK both in liver and
skeletal muscle, decreased hepatic glucose production
(down-regulation of PEPCK and G6Pase), and increased
protein contents of skeletal muscle GLUT4. These find-
ings indicate that S. alata could alleviate hyperglycemia,
hyperinsulinemia, hyperleptinemia, and adiposity by ac-
tivation of AMPK, which would lead to the improve-
ment of glucose homeostasis. Therefore, S. alata may be
beneficial for the management of obestity-related insulin
resistance and T2DM. The identification of active ingre-
dients of S. alata should be further studied.
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